-
Reckitt Benckiser Pharmaceuticals Inc. et al v. Par Pharmaceutical Inc. et al DC CAFC
- 1:14-cv-01573
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/31/2014
- Closed: 09/20/2017
- Latest Docket Entry: 11/16/2020
- PACER
- Docket updated daily
2
Plaintiffs
2
Defendants
2
Accused
Products
2
Patents-in-Suit
995
Days in
Litigation
-
Reckitt Benckiser Pharmaceuticals Inc. et al v. Par Pharmaceutical Inc. et al DC CAFC
- 1:14-cv-01573
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/31/2014
- Closed: 09/20/2017
- Latest Docket Entry: 11/16/2020
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
-
Infringement
IntelGenx Corporation
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
12 mg/3 mg dosage strengths Buprenorphine hydrochloride pursuant to ANDA No. 2058542 mg/0.5 mg4 mg/1 mg8 mg/2 mgBuprenorphine hydrochlorideBuprenorphine hydrochloride and naloxone hydrochloride sublingual filmnaloxone hydrochloride sublingual film | US 8,900,497 B2 |
24
|
No infringement
Entry 205Entry 224 Entry 203 |
Par Pharmaceutical, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
12 mg/3 mg dosage strengths Buprenorphine hydrochloride pursuant to ANDA No. 2058542 mg/0.5 mg4 mg/1 mg8 mg/2 mgBuprenorphine hydrochlorideBuprenorphine hydrochloride and naloxone hydrochloride sublingual filmnaloxone hydrochloride sublingual film | US 8,900,497 B2 |
24
|
No infringement
Entry 205Entry 224 Entry 203 |